• Open Access

Identification and functional screening of microRNAs highly deregulated in colorectal cancer

Authors

  • Petra Faltejskova,

    1. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    2. Central European Institute of Technology (CEITEC), Brno, Czech Republic
    Search for more papers by this author
  • Marek Svoboda,

    1. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    2. Central European Institute of Technology (CEITEC), Brno, Czech Republic
    Search for more papers by this author
  • Klara Srutova,

    1. Central European Institute of Technology (CEITEC), Brno, Czech Republic
    Search for more papers by this author
  • Jitka Mlcochova,

    1. Central European Institute of Technology (CEITEC), Brno, Czech Republic
    Search for more papers by this author
  • Andrej Besse,

    1. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    2. Central European Institute of Technology (CEITEC), Brno, Czech Republic
    Search for more papers by this author
  • Jana Nekvindova,

    1. Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine and Faculty Hospital in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
    Search for more papers by this author
  • Lenka Radova,

    1. Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
    Search for more papers by this author
  • Pavel Fabian,

    1. Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    Search for more papers by this author
  • Katerina Slaba,

    1. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    Search for more papers by this author
  • Igor Kiss,

    1. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    Search for more papers by this author
  • Rostislav Vyzula,

    1. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    Search for more papers by this author
  • Ondrej Slaby

    Corresponding author
    1. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute (MMCI), Brno, Czech Republic
    2. Central European Institute of Technology (CEITEC), Brno, Czech Republic
    • Correspondence to: Dr Ondrej SLABY, Ph.D.,

      Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53 Brno, Czech Republic.

      Tel.: +420543136902

      Fax: +420543136902

      E-mail: on.slaby@gmail.com

    Search for more papers by this author

Abstract

MicroRNAs (miRNAs) constitute a robust regulatory network with post-transcriptional regulatory efficiency for almost one half of human coding genes, including oncogenes and tumour suppressors. We determined the expression profile of 667 miRNAs in colorectal cancer (CRC) tissues and paired non-tumoural tissues and identified 42 differentially expressed miRNAs. We chose miR-215, miR-375, miR-378, miR-422a and miR-135b for further validation on an independent cohort of 125 clinically characterized CRC patients and for in vitro analyses. MiR-215, miR-375, miR-378 and miR-422a were significantly decreased, whereas miR-135b was increased in CRC tumour tissues. Levels of miR-215 and miR-422a correlated with clinical stage. MiR-135b was associated with higher pre-operative serum levels of CEA and CA19-9. In vitro analyses showed that ectopic expression of miR-215 decreases viability and migration, increases apoptosis and promotes cell cycle arrest in DLD-1 and HCT-116 colon cancer cell lines. Similarly, overexpression of miR-375 and inhibition of miR-135b led to decreased viability. Finally, restoration of miR-378, miR-422a and miR-375 inhibited G1/S transition. These findings indicate that miR-378, miR-375, miR-422a and miR-215 play an important role in CRC as tumour suppressors, whereas miR-135b functions as an oncogene; both groups of miRNA contribute to CRC pathogenesis.

Ancillary